Verisk Analytics stock price target maintained at $230 by RBC Capital
RBC Capital maintained an Outperform rating and $230 price target for Verisk Analytics (VRSK), citing undervaluation and growth prospects. The company expects 7% Q3 2026 organic revenue growth, driven by government contracts and GenAI adoption. Verisk reported Q2 earnings and revenue slightly above estimates, with a P/E ratio of 27.87. BMO Capital raised its price target to $248. The company is appealing a court decision related to its acquisition of AccuLynx.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the maintained $230 target and Outperform stance, which can influence positioning, but it does not introduce a new Verisk disclosure beyond what is already known (it references prior earnings and an ongoing appeal).
Market read
Analyst reiteration provides modest sentiment support, but the article lacks a fresh, primary Verisk catalyst (no new guidance, deal, or regulatory action).
What to watch
International travel insurance headwinds from geopolitical tensions and softer commercial property volumes could offset the organic growth narrative, limiting near-term multiple expansion.
Background
The piece frames a RBC Capital reiteration for Verisk, alongside general market weakness tied to tech and hot PPI.
Ticker impact
RBC Capital reiterated an Outperform rating and maintained a $230 price target on Verisk, citing ~7% Q3 organic growth and GenAI/anti-fraud momentum.
Likely mild upward bias as traders weigh maintained upside targets against the stock’s current valuation and the cited growth drivers.
The only company-specific trading input is an analyst reiteration with forward-looking estimates; it is not a fresh earnings/guidance print or a new legal/M&A development.
Market effects
Supports sentiment for insurance data and risk analytics names via continued emphasis on anti-fraud adoption and GenAI uptake.
None explicit beyond a broad US market open context (Nasdaq down, S&P/Dow mixed).
Mentions geopolitical tensions affecting international travel insurance, but no direct cross-border policy action.
Counterpoint
The article’s upside case relies on easy comparisons and early-stage GenAI uptake, which may not translate into durable acceleration.
Key entities
- companyVerisk Analytics
Insurance, energy, and financial services data analytics provider; subject of the RBC price-target reiteration and referenced legal appeal.
- analyst_firmRBC Capital
Maintained Outperform rating and $230 price target, citing organic growth drivers and valuation metrics.
- courtDelaware Supreme Court
Referenced as the venue for Verisk’s appeal related to its Exactlogix/AccuLynx merger condition to closing.
